Physostigmine in choreiform movement disorders.
D000109:Acetylcholine / Q000378:metabolism; D000328:Adult; D000368:Aged; D001154:Art; D001264:Athetosis / Q000139:chemically induced; D002819:Chorea / Q000139:chemically induced / Q000188:drug therapy*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006236:Handwriting; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009048:Motor Skills / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy; D010640:Phenothiazines / Q000627:therapeutic use; D010830:Physostigmine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011187:Posture / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects
D010640:Phenothiazines; D004295:Dihydroxyphenylalanine; D010830:Physostigmine; D000109:Acetylcholine